|
Q4 FY2014
As of Dec 31, 2014
|
Q3 FY2014
As of Sep 30, 2014
|
Q2 FY2014
As of Jun 30, 2014
|
Q1 FY2014
As of Mar 31, 2014
|
Q4 FY2013
As of Dec 31, 2013
|
Q3 FY2013
As of Sep 30, 2013
|
Q2 FY2013
As of Jun 30, 2013
|
Q1 FY2013
As of Mar 31, 2013
|
Q4 FY2012
As of Dec 31, 2012
|
Q3 FY2012
As of Sep 30, 2012
|
Q2 FY2012
As of Jun 30, 2012
|
Q1 FY2012
As of Mar 31, 2012
|
Q4 FY2011
As of Dec 31, 2011
|
Q3 FY2011
As of Sep 30, 2011
|
Q2 FY2011
As of Jun 30, 2011
|
Q1 FY2011
As of Mar 31, 2011
|
Q4 FY2010
As of Dec 31, 2010
|
Q3 FY2010
As of Sep 30, 2010
|
Q2 FY2010
As of Jun 30, 2010
|
Q1 FY2010
As of Mar 31, 2010
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and equivalents | ||||||||||||||||||||
| Short-term investments | ||||||||||||||||||||
| Trade receivables, net | ||||||||||||||||||||
| Inventories | ||||||||||||||||||||
| Other current assets | ||||||||||||||||||||
| Assets of discontinued operations | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Investments and other assets | ||||||||||||||||||||
| Deferred tax assets | ||||||||||||||||||||
| Property, plant and equipment, net | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Intangibles, net | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND EQUITY | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Notes payable | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued compensation | ||||||||||||||||||||
| Other accrued expenses | ||||||||||||||||||||
| Income taxes | ||||||||||||||||||||
| Liabilities of discontinued operations | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Long-term debt | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Equity: | ||||||||||||||||||||
| Allergan, Inc. stockholders' equity: | ||||||||||||||||||||
| Preferred stock, $.01 par value; authorized 5,000,000 shares; none issued | ||||||||||||||||||||
| Common stock, $.01 par value; authorized 500,000,000 shares; issued 307,605,860 and 307,554,060 shares as of December 31, 2014 and 2013, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Stockholders' equity subtotal before treasury stock | ||||||||||||||||||||
| Less treasury stock, at cost (8,373,176 and 9,947,345 shares as of December 31, 2014 and 2013, respectively) | ||||||||||||||||||||
| Total stockholders' equity | ||||||||||||||||||||
| Noncontrolling interest | ||||||||||||||||||||
| Total equity | ||||||||||||||||||||
| Total liabilities and equity | ||||||||||||||||||||
Loading...
